Home
Septerna, Inc.

Septerna, Inc. Market Share Analysis for April 2026

Careers - Septerna

Health > Biotechnology and Pharmaceuticals

Domainsepterna.com

Year Founded2019

Employees51 - 200

Annual Revenue< $1M

Septerna, Inc.

Septerna, Inc. (including company regionals)

septerna.com

See more website traffic and engagement information

Septerna, Inc. Revenue up to April 2026 is < 1M

revenue generated by Septerna, Inc. top domains

Septerna, Inc. top domains revenue over 3 years

Revenue for Septerna, Inc. top domains

septerna.com< 1M

See more with Sales Intelligence

Total visits to Septerna, Inc.'s top domains

Understand Septerna, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

septerna.com6.5K

See more with Sales Intelligence

Avg. visit duration in Septerna, Inc.'s top domains

Analyze Septerna, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

septerna.com00:00:31

See more with Sales Intelligence

Avg. pageviews on Septerna, Inc.'s top domains

See how Septerna, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

septerna.com2.15

See more with Sales Intelligence

Septerna, Inc. top competitors by domain

Top similar sites in April 2026, ranked by their affinity

fortressbiotech.comCompany NameFortress BiotechEmployees51 - 200HQUnited States, Florida, MiamiAnnual revenue$50M - $75MTotal visits11.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Septerna, Inc.

These are the website technologies, by industry, used by Septerna, Inc. top domains

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

Marketing (2)

Google Marketing Platform

Mobile (2)

Meta Viewport

More Technologies

10

See all

News & Signals from Septerna, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSepterna, Inc. has revenue of $26.5M.Septerna (NASDAQ: SEPN) grows Q1 revenue to $26.5M, trims loss.

NewsSepterna, Inc. is developing SEP-479 for hypoparathyroidism.Septerna (nasdaq: SEPN) begins Phase 1 trial of SEP-479 for hypoparathyroidism.

NewsSepterna, Inc. is developing SEP-479.Septerna is developing SEP-479, a potent oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist, for the treatment of patients with hypoparathyroidism.